Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 2 7Phase 1/2 5Phase 3 4

Status

Completed 5Active not recruiting 2

Sponsor Class

OTHER 10INDUSTRY 7NIH 5NETWORK 1

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Stomach Neoplasms 1Solid Tumors 1Ovarian Neoplasms 1Neoplasms, Unknown Primary 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × ipatasertib × Clear all
NCT04589845 2026-05-08

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Hoffmann-La Roche

Phase 2 Active not recruiting
920 enrolled 1 FDA
Other solid neoplasm

Solid Tumors

NCT04931342 2026-03-10

BOUQUET

Hoffmann-La Roche

Phase 2 Active not recruiting
176 enrolled
Gynecologic

Ovarian Neoplasms

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed
529 enrolled 16 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT04632992 2025-01-08

MyTACTIC

Genentech, Inc.

Phase 2 Completed
252 enrolled 27 charts

Advanced Unresectable or Metastatic Solid Malignancy

NCT01896531 2022-03-02

A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Genentech, Inc.

Phase 2 Completed
153 enrolled 16 charts
Gastrointestinal

Stomach Neoplasms

NCT02162719 2021-03-10

LOTUS

Genentech, Inc.

Phase 2 Completed
124 enrolled 26 charts
Breast

Breast Neoplasms

NCT02301988 2018-10-17

A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer

Genentech, Inc.

Phase 2 Completed
151 enrolled 22 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡